Dr Mark Fyvie
Dr Fyvie is an entrepreneur focusing on technology ventures based on innovative business models. He most recently founded Vx Pharma, a phase 1-4 clinical trials business. Dr Fyvie has managed Vx Pharma as CEO since inception and has focused the business on therapeutic areas most affecting the developing world most especially HIV.
Prior to Vx Pharma, Dr Fyvie served as CEO and founding member of the Cape Biotech Investment Trust (government funded stimulus programme) funding and incubating VC investments in excess of $100m in new life-science ventures. Of the portfolio of companies at Cape Biotech one investment exited to a major multinational pharmaceutical company at circa 100x multiple: the largest technology exit in the history of South Africa.
As an internationally credentialed business strategy consultant, Dr Fyvie has deployed his expertise in unlocking novel innovation value through deep commercialisation strategies for pharmaceutical, biotech, clinical research, and e-finance organisations including FirstRand Bank, Liberty Health and Accenture where he worked in the business strategy practice.
Dr Fyvie serves on numerous Boards and donates significant time to pro bono work in the South African innovation system. He holds a PhD from the University of Cambridge.